This move is archived. Current quotes and coverage live on the stock page.
Get MDP alerts:
Medexus Pharmaceuticals Inc (MDP.TO) has seen a notable uptick in its stock price, closing at CA$4.02, reflecting a 0.75% increase in the last trading session.
Investors are taking notice as Medexus experiences a positive shift in its stock performance. This upward movement is a welcome sign for shareholders, especially in a market that can often be unpredictable.
Investor takeaway: For investors, the recent gain in Medexus Pharmaceuticals Inc's stock could indicate growing confidence in the company's future prospects, particularly regarding its product GRAFAPEX (treosulfan) for Injection.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$159.02M
52W high
$5.50
52W low
$2.51
1W change
-3.44%
Beta
1.83
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 43.3% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+43.3% Upside
Current Price
C$5.06
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
32.7%
Annualized
90-Day Vol
40.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.05
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.37 | C$4.80 โ C$6.01 |
| 60 trading days | C$5.70 | C$4.86 โ C$6.68 |
| 90 trading days | C$6.05 | C$4.98 โ C$7.35 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medexus Pharmaceuticals Inc Gains 0.75% in Latest Trading Session
The stock's market cap stands at CA$135 million, highlighting its position in the healthcare sector as it navigates competitive challenges.
Bull case
The increase in stock price may reflect optimism surrounding Medexus's ongoing developments and product performance, especially with GRAFAPEX, which has shown strong results this year. This momentum could attract further investment and strengthen the company's market position.
Bear case
Despite the recent gain, investors should remain cautious. The stock's performance is still subject to market volatility, and the lack of significant news could mean that the increase is more speculative than based on solid fundamentals.
Advertisement
Recent Performance Overview
Medexus Pharmaceuticals Inc has seen a slight uptick in its stock price, closing at CA$4.02, which is a 0.75% gain from the previous session. This performance could indicate a positive shift in investor sentiment as the company continues to focus on its key product, GRAFAPEX.
Market Sentiment and Future Outlook
The recent gain in Medexus's stock price may suggest growing confidence among investors regarding the company's strategies and product performance. With no recent news updates, the market's reaction could be based on anticipation of future developments, especially as Medexus continues to navigate its competitive landscape.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
